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Abstract
Aim—The aim of this study was to determine the population pharmacokinetics of darbepoetin alfa
in hypothermic neonates with hypoxic-ischemic encephalopathy treated with hypothermia.
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Methods—Neonates ≥36 weeks gestation and <12 h postpartum with moderate to severe
hypoxic-ischemic encephalopathy who were undergoing hypothermia treatment were recruited in
this randomized, multicenter, investigational, new drug pharmacokinetic study. Two intravenous
darbepoetin alfa treatment groups were evaluated: 2 and 10 μg/kg. Serum erythropoietin
concentrations were measured using an enzyme-linked immunosorbent assay. Monolix 4.3.1 was
used to estimate darbepoetin alfa clearance and volume of distribution. Covariates tested included:
birthweight, gestational age, postnatal age, postmenstrual age, sex, Sarnat score, and study site.

Author Manuscript

Results—Darbepoetin alfa pharmacokinetics were well described by a one-compartment model
with exponential error. Clearance and the volume of distribution were scaled by birthweight
(centered on the mean) a priori. Additionally, gestational age (also centered on the mean)
significantly affected darbepoetin alfa clearance. Clearance and volume of distribution were
estimated as 0.0465 L/h (95 % confidence interval 0.0392–0.0537) and 1.58 L (95 % confidence
interval 1.29–1.87), respectively.
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Conclusions—A one-compartment model successfully described the pharmacokinetics of
darbepoetin alfa among hypothermic neonates treated for hypoxic-ischemic encephalopathy.
Clearance decreased with increasing gestational age.

1 Introduction

Author Manuscript

Hypoxic-ischemic encephalopathy (HIE) affects 1.5 infants per 1000 live births in developed
countries [1]. Moderate to severe HIE is associated with severe disabilities in one in four
survivors and a mortality of 15–25 % [2, 3]. Common disabilities include significant motor
deficits, cerebral palsy, and persistent developmental delays [2, 3]. The standard of care for
HIE is moderate hypothermia, in which the neonate is cooled to 33.5°C within 6 h of birth
and hypothermia is maintained for 72 h [4–6]. A meta-analysis published by Edwards et al.
[3] evaluated the neurologic outcomes of infants who were randomized to receive moderate
hypothermia or normothermia and compared their clinical outcomes after a minimum of 18
months of follow-up. The authors found that the case fatality rate decreased from 33 to 26 %
and abnormal neurologic outcomes at 18–22 months decreased from 40 to 28 % comparing
normothermia with moderate hypothermia, respectively. A similar analysis by Tagin et al.
[7] with 1214 newborns found that with hypothermia treatment, the risk ratio of death or
major neurodevelopmental disability was 0.76 (95 % confidence interval 0.69–0.84) and the
rate of survival with normal neurologic function at 18 months of age was improved (1.64;
1.36–1.95). While these results are encouraging, moderate to severe HIE despite
hypothermia treatment still causes substantial mortality and morbidity, which supports the
need for adjunctive therapies to improve outcomes.
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Erythropoietin-stimulating agents have been shown to mediate adaptive tissue responses
following stressful insults and may be neuroprotective [8, 9]. This is consistent with studies
that have shown that the erythropoietin receptor is expressed throughout the human brain
[10–12]. Preclinical studies using mice demonstrated that erythropoietin efficiently crosses
the blood-brain barrier [13]. Daily administration of erythropoietin to animals has conferred
histologic and behavioral neuroprotection after experimental intracerebral hemorrhage [14].
In two clinical trials, erythropoietin was found to exert neuroprotective effects among
neonates who did not undergo hypothermia treatment [15, 16]. More recently, the Neonatal
Erythropoietin in Asphyxiated Term Neonates trial showed that erythropoietin could be
administered safely to neonates undergoing therapeutic hypothermia [17].
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Darbepoetin alfa is a synthetic molecule designed to mimic the effects of erythropoietin [18–
20]. Site-directed mutagenesis at five amino acid locations (Ala30Asn, His32Thr, Pro87Val,
Trp88Asn, and Pro90Thr) added two additional N-linked carbohydrate chains, which extend
the half-life [18–20]. Preclinical studies with darbepoetin alfa have shown that it crosses the
blood-brain barrier and displays comparable neuroprotective activity when compared with
erythropoietin [13, 21]. In animal models, weekly administration of darbepoetin alfa
conferred histologic and behavioral neuroprotection after experimental intracerebral
hemorrhage [14]. Early clinical studies have demonstrated the safety of darbepoetin alfa
among preterm and term neonates [22, 23]. The aim of this study was to determine the
population pharmacokinetics of darbepoetin alfa among neonates undergoing therapeutic
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hypothermia for the treatment of HIE in support of larger studies to evaluate its efficacy for
neuroprotection.

2 Methods
2.1 Subjects and Study Design
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This was a multicenter, placebo-controlled, randomized, double-blind, pharmacokinetic and
safety trial that was approved by each site’s institutional review board (NCT01471015). The
population pharmacokinetic analysis of this trial is described herein. Centers included the
Seattle Children’s Hospital, Primary Children’s Hospital, University of Utah Hospital,
Intermountain Medical Center, McKay-Dee Hospital, Vanderbilt Children’s Hospital, and
the University of New Mexico Children’s Hospital. Parental permission was obtained before
conducting any study procedures. Inclusion criteria included: gestational age ≥36 weeks,
<12 h of age; evidence of moderate to severe hypothermia based on a modified Sarnat score
of 2–3 [4]; and severe fetal or early (< 1 h of age) neonatal acidosis. Additional criteria
included evidence of an acute intrauterine event, and either a 10-min Apgar score of ≤5 or
assisted ventilation initiated at birth that continued for ≥10 min was required if a blood gas
was not available or a blood gas at <1 h of age had a pH between 7.01 and 7.15, or a base
deficit between 10 and 15.9 mEg/L. Neonates were excluded from the trial if they had a
major congenital and/or chromosomal abnormality, severe growth restriction (≤1800 g at
birth), a prenatal diagnosis of brain abnormality or hydrocephalus, a hematocrit >65 %, a
platelet count >600,000/dL, neutropenia (absolute neutrophil count <500 μL), were
receiving extracorporeal membrane oxygenation, or had a maternal history of major vascular
thrombosis or multiple fetal losses (three or more spontaneous abortions).
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Following informed consent, patients were randomized to one of three study arms: placebo
(saline), 2 μg/kg, or 10 μg/kg darbepoetin alfa (Aranesp®, Amgen, Thousand Oaks, CA,
USA). All three groups received therapeutic hypothermia according to the standard of care
within 6 h of birth, which was maintained for 72 h. Neonates received the darbepoetin alfa
or placebo dose intravenously over 5 min within 12 h of life, followed by a 2-mL saline
flush over 5 min.
2.2 Sample Collection
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Plasma samples were collected according to a population design, in which patients were
randomized to one of two sampling schedules in a 1:1 ratio. One group had samples
collected before treatment and at 4, 12, 24, and 60 h post-dose. The second group had
samples collected before treatment and at 4, 18, 36, and 72 h post-dose. All blood samples
were collected by a heel stick or from an arterial or central venous catheter.
2.3 Analytical Assay
Plasma samples were analyzed using a Quantikine IVD™ human erythropoietin ELISA
(R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. This
ELISA cross-reacts with endogenous erythropoietin, which makes it impossible to
distinguish darbepoetin alfa from endogenous erythropoietin. Standard curves included 2.5
[lower limit of quantification (LLOQ)], 5.0, 20, 50, 100, and 200 mU/mL of erythropoietin.
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A weighted (1/x2) quadratic regression model was fitted to each standard curve. Each
individual sample well was quantified by interpolation, after which, duplicates were
averaged. Samples that were below the LLOQ were excluded from the analysis (eight
concentrations, 14 %). If samples were evaluated on more than 1 day, all wells were
averaged for the final sample quantitation. Duplicates in the standard curve that had an
intraday coefficient of variation >10 % or samples that had intra- or inter-day coefficients of
variation >10 % were excluded from the analysis. In addition, standards that did not meet
the United States Food and Drug Administration guidelines (±20 % for LLOQ, ±15 % for all
others) were not included in the construction of the standard curve.
2.4 Pharmacokinetic Analysis
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All darbepoetin alfa-treated concentrations were normalized to the median placebo
concentration at the corresponding sampling time to account for the effect of endogenous
erythropoietin contributions. Darbepoetin alfa pharmacokinetic parameters were estimated
using a nonlinear mixed-effects model that was implemented in Monolix 4.3.1 (Lixoft,
Orasy, France) using the stochastic approximation expectation maximization algorithm [24]
combined with a Markov Chain Monte Carlo procedure. The number of Markov Chain
Monte Carlo chains was fixed to four. One- and two-compartment structural models were
evaluated and selected based on their goodness of fit. Model stability was assessed by
altering the initial estimates for darbepoetin alfa clearance and volume of distribution.
Unstable models and those that produced erroneous results (e.g., negative parameter
estimates) were disregarded. Diagnostic plots were used to assess the model’s fit. Individual
weighted residuals were plotted vs. time and individual predictions. Models were compared
by assessing the biological plausibility of the parameter estimates, the variability of the
parameter estimates, and the −2 × log likelihood or the objective function value (OFV).
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Model variability and random effects were classified as one of two types of error: betweensubject variability (BSV) and residual unexplained variability (RUV). BSV was assumed to
be log-normally distributed according to an exponential equation:
(1)

Author Manuscript

where Pi, is the pharmacokinetic parameter of the ith individual, θpop is the population mean
for P, and η represents the normally distributed between-subject random effect with a mean
of zero and a variance of ω2. Additive, proportional, combined additive and proportional,
and exponential RUV error models were evaluated. The final model used an exponential
model of the form:
(2)
where Yij is the observed concentration for the ith individual at time j, Ŷij is the individual
predicted concentration, and ε represents the normally distributed error term with a mean of
zero and variance of σ2 .
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Several patient characteristics were tested for their influence on darbepoetin alfa
pharmacokinetic parameters. The covariates that were tested included birthweight,
gestational age, postnatal age, postmenstrual age, sex, Sarnat score, and study site.
Birthweight centered on the mean was included a priori in the model for both clearance and
the volume of distribution on the basis of its biological plausibility [25]. In addition,
exponents were fixed at 1 based on model estimates of 1.2 and 0.992. Power, exponential,
and linear models were evaluated for the remaining covariates. In addition, each covariate
was also evaluated after it was centered on the population mean. Forward addition was used
to determine significant covariates. A decrease in the OFV ≥3.84 was considered significant
for 1 df at p = 0.05 based on the χ2 distribution. Backward elimination was used to remove
covariates from the model with an increase in the OFV ≥6.63 corresponding to 1 df at p =
0.01.
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2.6 Model Evaluation
Base and final models were evaluated using goodness-of-fit plots. Observed drug
concentrations were inspected for their correlation with predicted concentrations. The −2
and +2 region criterion was used to assess the individual weighted residual plots that were
constructed. Uncertainty in pharmacokinetic parameter estimates was quantitatively assessed
by calculating standard errors and 95 % confidence intervals for all pharmacokinetic
parameter estimates. Additionally, normalized prediction distribution errors were plotted
against time and population-predicted darbepoetin alfa concentrations to assess for model
misspecification. A prediction-corrected visual predictive check was also performed by
simulating 1000 darbepoetin alfa concentrations at each time point [26].
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3 Results
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There were 10 patients with 32 concentration measurements who were randomized to the
placebo group. In addition, there were 16 patients with 63 concentration measurements who
received darbepoetin alfa. Supplemental Fig. 1 depicts the time-concentration curve of all
patients. The demographics for the study subjects at the time of the dose are included in
Table 1. The data were well described by a one-compartment model with zero-order input
and first-order elimination as assessed by visual inspection of the diagnostic plots and the
significant reduction of the OFV. After a priori inclusion of birthweight on clearance and the
volume of distribution, additional covariate analyses indicated that gestational age centered
on the mean exerted a significant influence on darbepoetin alfa clearance (decreasing BSV
from 0.328 to 0.205, Supplemental Fig. 2). After including these covariates, no other
covariates were found to significantly affect darbepoetin alfa pharmacokinetics. The final
model estimates are presented in Table 2 and were derived from the following final model:

(3)
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(4)
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where CLi is the individual clearance, CLpop is the estimated population clearance, BWTi is
the individual birth-weight, BWTpop is the mean population birthweight, GAi is the
individual gestational age, GApop is the mean population gestational age, and θ is the
estimated exponent for the effect of gestational age on darbepoetin alfa clearance. Similarly,
Vi is the individual volume of distribution, Vpop is the population estimate, BWTi is the
individual weight, and BWTpop is the mean population birthweight. Diagnostic plots were
visually inspected to confirm the selection of the final model (Fig. 1a, b). To further evaluate
the model, individual weighted residual and normalized prediction distribution error plots
were examined (Fig. 2a–d). The data were equally distributed around zero and were in the
−2to +2 range. Additionally, data were simulated to produce a visual predictive check
comparing the 10th, 50th, and 90th percentiles (Fig. 3). The majority of the simulations were
within these ranges, demonstrating acceptable agreement between observed concentrations
and simulated darbepoetin alfa concentrations.

4 Discussion
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This is the first study to evaluate the pharmacokinetics of darbepoetin alfa among neonates
with HIE undergoing therapeutic hypothermia. This study also featured a placebo arm, such
that endogenous erythropoietin concentrations could be used to normalize erythropoietin
concentrations for the darbepoetin alfa-treated patients. This study demonstrated that
darbepoetin alfa pharmacokinetics in neonates with HIE was well described by a onecompartment model, with a population clearance equal to 0.0465 L/h (0.015 L/h/kg) and
volume of distribution equal to 1.58 L (0.511 L/kg). Covariate analyses indicated that after
the inclusion of birthweight on volume of distribution and clearance, gestational age also
significantly affected clearance, with increasing gestational age associated with decreased
darbepoetin alfa clearance. Darbepoetin alfa is a synthetic derivative of erythropoietin and is
primarily cleared by binding to erythropoietin receptors on progenitor cells [27–32]. It has
been demonstrated in lambs that the clearance of erythropoietin occurs most rapidly in
fetuses and gets progressively lower as sheep mature to adulthood [33], supporting the
findings of this study.
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A majority of the adult pharmacokinetic studies pooled data from patients who received
darbepoetin alfa intravenously and via subcutaneous injection [34–36]. These studies used a
two-compartment model to describe darbepoetin alfa pharmacokinetics [34–36]. It is unclear
whether the one-compartment model used in the current study performed better than the
two-compartment model because of sparse sampling in this vulnerable neonatal population
or whether the pharmacokinetics of darbepoetin alfa are better represented by a onecompartment model in neonates rather than the two-compartment model seen in adults. The
only other study to evaluate intravenous darbepoetin alfa pharmacokinetics in neonates was
conducted in 10 anemic patients with a mean gestational age of 31.1 weeks at birth who did
not have HIE [22]. The authors found that darbepoetin alfa pharmacokinetics were best
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 26.
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described using a mono-exponential model; however, two patients were better fit with a
dual-exponential pharmacokinetic model. The mean volume of distribution and clearance
were 1.29 L and 0.0882 L/h, respectively, resulting in a half-life of about 10.1 h. The
population estimates reported herein resulted in a half-life of 23.6 h. Patients in this
population analysis were on average 7 weeks older at birth than those in the study conducted
by Warwood et al. [22]. Unlike prior studies, the current analysis adopted a population
pharmacokinetic approach, which allowed for the identification of influential covariates that
were used to reduce the proportion of unexplained variability in darbepoetin alfa
pharmacokinetic parameters. The population pharmacokinetic model revealed that after
accounting for the influence of birthweight, darbepoetin alfa clearance was inversely
correlated with gestational age. This finding suggests that the difference in the mean
gestational age of the cohort studied by Warwood et al. and that of the cohort included in
this analysis may explain, at least in part, the difference in darbepoetin alfa half-lives
reported previously and those observed in this study. Additionally, patients in our study were
also treated with hypothermia. It is therefore unclear whether the differences in half-lives
between these studies can be attributed to differences in gestational age, the use of
therapeutic hypothermia, other unmeasured factors, or a combination of the above.
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Some limitations should be considered when interpreting this study’s findings. First, patients
had differing lengths of hypoxic episodes, which were not quantifiable. Hypoxic episodes
increase erythropoietin production and it is believed that longer hypoxic episodes result in
more erythropoietin production [37]. Even with a representative placebo group, it is possible
that early darbepoetin alfa concentrations may have been overestimated because of higher
endogenous erythropoietin concentrations at birth among darbepoetin alfa-treated patients.
Second, the assay used quantifies both darbepoetin alfa and erythropoietin, and as such,
median concentrations from placebo patients had to be used as a baseline for the treated
patients. Furthermore, a specific validation for this assay has not been completed in
neonates, though this assay has been used previously for darbepoetin alfa quantification
[38]. Additionally, the confidence interval for the BSV for the volume of distribution
includes zero, which could be attributed to the sparse sampling that was needed to ethically
and practically conduct this neonatal pharmacokinetic trial. With a larger number of subjects
and/or additional concentration measurements, it may be possible to improve the precision
of the BSV estimate for the volume of distribution. Furthermore, the relatively large RUV
observed in this study (42 %) is in agreement with previous neonatal drug studies and
emphasizes the difficulty in determining precise pharmacokinetic parameter estimates in this
highly variable patient population, which undergoes profound developmental changes over
the first few weeks of life [39]. Last, choosing to include birthweight a priori in the model
could decrease the predictive performance of the model with the addition of other covariates.
However, because of biological plausibility, we deemed it important to include birthweight
in the model as a covariate before testing other covariates.

5 Conclusions
This study presents the first population pharmacokinetic analysis of darbepoetin alfa in
hypothermic neonates with HIE. This study demonstrated that after accounting for the effect
of birthweight on clearance and the volume of distribution, gestational age also significantly
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 26.
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affected darbepoetin alfa clearance. Gestational age was inversely correlated with clearance,
confirming results obtained in earlier studies involving fetal, neonatal, and adult sheep.
Future analyses with larger numbers of subjects and long-term follow-up are warranted to
further characterize the pharmacokinetics of darbepoetin alfa and their influence on clinical
outcomes, including death and severe disability.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
A population pharmacokinetic model for darbepoetin alfa in neonates with hypoxicischemic encephalopathy was developed.
After a priori inclusion of birthweight on the volume of distribution and clearance,
gestational age was inversely correlated with darbepoetin alfa clearance.
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Fig. 1.

Observed erythropoietin concentrations vs. population-and individual-predicted
erythropoietin concentrations for hypothermic darbepoetin alfa-treated neonates are
presented in a and b, respectively, for the final model. The solid line represents the line of
reference and the dotted line represents the spline of the model
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Fig. 2.

The individual weighted residuals (IWRES) and normalized prediction distribution errors
(NPDE) vs. time- and population-predicted erythropoietin concentrations are presented in a–
d. The solid line is the reference line at zero
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Fig. 3.

Visual predictive check of the final neonatal darbepoetin alfa model. The blue shading
represents the 10th and 90th percentiles. Pink shading represents the 50th percentile. The
open circles and red shading represent data that did not fall within the 10th, 50th, or 90th
percentiles. emp empirical, prctile percentile
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Patient demographics
Characteristic

Placebo (n = 10)a

Darbepoetin alfa (n = 16)a

Sex (male)

4

10

GA (weeks)

38.1 ± 1.7

38.4 ± 1.2

PNA (h)

9.0 ± 1.4

9.7 ± 2.2

PMA (weeks)

38.1 ± 1.7

38.4 ± 1.1

BWT (kg)

3.09 ± 0.39

3.03 ± 0.43

2

8

10

3

2

6

Sarnat scoreb

BWT birthweight, GA gestational age, HIE hypoxic ischemic encephalopathy, PMA postmenstrual age, PNA postnatal age

Author Manuscript

a

n or mean ± standard deviation

b

The Sarnat Grading Scale of Hypoxic Ischemic Encephalopathy is a scoring system used to grade the severity of an HIE injury. Scores of 2 and 3
represent moderate and severe HIE injuries, respectively

Author Manuscript
Author Manuscript
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 26.

Roberts et al.

Page 16

Table 2
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Final model parameter estimates
Parameters

Mean parameter estimate

95 % confidence interval

V (L)

1.58

1.29–1.87

CL (L/h)

0.0465

0.0392–0.0537

θ

10.8

5.50–15.7

V

0.153

−0.161 to 0.467

CL

0.205

0.054–0.356

σ-RUV

0.421

0.325–0.517

ω-BSV

CL clearance, BSV between-subject variability, RUV residual unexplained variability, V volume of distribution, θ represents the model-estimated
coefficient for the effect of gestational age (weeks) on darbepoetin alfa clearance
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